{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:48:57Z","timestamp":1794642537167,"version":"4.9.1"},"reference-count":107,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Alzheimer\u2019s disease is one of the most progressive forms of dementia, ultimately leading\nto death in aged populations. The major hallmarks of Alzheimer\u2019s disease include deposition of\nextracellular amyloid senile plaques and intracellular neurofibrillary tangles in brain neuronal cells.\nAlthough there are classical therapeutic options available for the treatment of the diseases, however,\nthey provide only a symptomatic relief and do not modify the molecular pathophysiological course\nof the disease. Recent research advances in Alzheimer\u2019s disease have highlighted the potential role\nof anti-amyloid, anti-tau, and anti-inflammatory therapies. However, these therapies are still in different\nphases of pre-clinical\/clinical development. In addition, drug repositioning\/repurposing is\nanother interesting and promising approach to explore rationalized options for the treatment of Alzheimer\u2019s\ndisease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>This review discusses the different aspects of the pathophysiological mechanism involved in the\nprogression of Alzheimer\u2019s disease along with the limitations of current therapies. Furthermore, this\nreview also highlights emerging investigational drugs along with recent drug repurposing approaches\nfor Alzheimer\u2019s disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x18666200128121920","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T13:34:57Z","timestamp":1580218497000},"page":"868-882","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Recent Trends in the Management of Alzheimer\u2019s Disease: Current Therapeutic Options and Drug Repurposing Approaches"],"prefix":"10.2174","volume":"18","author":[{"given":"Rakesh K.","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Amity Institute of Pharmacy, Amity University, Manesar, Gurgaon-122413, Haryana,India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev-neuro-070815-014015","volume":"39","author":"Sala Frigerio C.","year":"2016","unstructured":"Sala Frigerio C.; De Strooper B.; Alzheimer\u2019s disease mechanisms and emerging roads to novel therapeutics. Annu Rev Neurosci 2016,39,57-79","journal-title":"Annu Rev Neurosci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1017\/S135561771700100X","volume":"23","author":"Bondi M.W.","year":"2017","unstructured":"Bondi M.W.; Edmonds E.C.; Salmon D.P.; Alzheimer\u2019s Disease: Past, Present, and Future. J Int Neuropsychol Soc 2017,23(9-10),818-831","journal-title":"J Int Neuropsychol Soc"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1515\/revneuro-2017-0006","volume":"28","author":"Kozlov S.","year":"2017","unstructured":"Kozlov S.; Afonin A.; Evsyukov I.; Bondarenko A.; Alzheimer\u2019s disease: as it was in the beginning. Rev Neurosci 2017,28(8),825-843","journal-title":"Rev Neurosci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.2174\/0929867323666161213101126","volume":"25","author":"Dos Santos Picanco L.C.","year":"2018","unstructured":"Dos Santos Picanco L.C.; Ozela P.F.; de Fatima de Brito Brito M.; Pinheiro A.A.; Padilha E.C.; Braga F.S.; de Paula da Silva C.H.T.; Dos Santos C.B.R.; Rosa J.M.C.; da Silva Hage-Melim L.I.; Alzheimer\u2019s Disease: A review from the pathophysiology to diagnosis, new perspectives for pharmacological treatment. Curr Med Chem 2018,25(26),3141-3159","journal-title":"Curr Med Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbr.2016.05.030","volume":"311","author":"Mufson E.J.","year":"2016","unstructured":"Mufson E.J.; Ikonomovic M.D.; Counts S.E.; Perez S.E.; Malek-Ahmadi M.; Scheff S.W.; Ginsberg S.D.; Molecular and cellular pathophysiology of preclinical Alzheimer\u2019s disease. Behav Brain Res 2016,311,54-69","journal-title":"Behav Brain Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000464422","volume":"24","author":"Sanabria-Castro A.","year":"2017","unstructured":"Sanabria-Castro A.; Alvarado-Echeverr\u00eda I.; Monge-Bonilla C.; Molecular pathogenesis of Alzheimer\u2019s Disease: An update. Ann Neurosci 2017,24(1),46-54","journal-title":"Ann Neurosci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","volume":"13","author":"Wang J.","year":"2017","unstructured":"Wang J.; Gu B.J.; Masters C.L.; Wang Y-J.; A systemic view of Alzheimer disease - insights from amyloid-\u03b2 metabolism beyond the brain. Nat Rev Neurol 2017,13(10),612-623","journal-title":"Nat Rev Neurol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","volume":"8","author":"Cummings J.","year":"2016","unstructured":"Cummings J.; Aisen P.S.; DuBois B.; Fr\u00f6lich L.; Jack C.R.; Jones R.W.; Morris J.C.; Raskin J.; Dowsett S.A.; Scheltens P.; Drug development in Alzheimer\u2019s disease: the path to 2025. Alzheimers Res Ther 2016,8,39","journal-title":"Alzheimers Res Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.trci.2016.05.001","volume":"2","author":"Van Eldik L.J.","year":"2016","unstructured":"Van Eldik L.J.; Carrillo M.C.; Cole P.E.; Feuerbach D.; Greenberg B.D.; Hendrix J.A.; Kennedy M.; Kozauer N.; Margolin R.A.; Molinuevo J.L.; Mueller R.; Ransohoff R.M.; Wilcock D.M.; Bain L.; Bales K.; The roles of inflammation and immune mechanisms in Alzheimer\u2019s disease. Alzheimers Dement (N Y) 2016,2(2),99-109","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=10","first-page":"641","volume":"27","author":"Kuca K.","year":"2016","unstructured":"Kuca K.; Soukup O.; Maresova P.; Korabecny J.; Nepovimova E.; Klimova B.; Honegr J.; Ramalhob T.C.; Fran\u00e7a T.C.C.; Current Approaches Against Alzheimer\u2019s Disease in Clinical Trials. J Braz Chem Soc 2016,27(4),641-649","journal-title":"J Braz Chem Soc"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrd3869","volume":"11","author":"Corbett A.","year":"2012","unstructured":"Corbett A.; Pickett J.; Burns A.; Corcoran J.; Dunnett S.B.; Edison P.; Hagan J.J.; Holmes C.; Jones E.; Katona C.; Kearns I.; Kehoe P.; Mudher A.; Passmore A.; Shepherd N.; Walsh F.; Ballard C.; Drug repositioning for Alzheimer\u2019s disease. Nat Rev Drug Discov 2012,11(11),833-846","journal-title":"Nat Rev Drug Discov"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","volume":"4","author":"Cummings J.","year":"2018","unstructured":"Cummings J.; Lee G.; Ritter A.; Zhong K.; Alzheimer\u2019s disease drug development pipeline. Alzheimers Dement (N Y) 2018,4,195-214","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","volume":"67","author":"Kumar A.","year":"2015","unstructured":"Kumar A.; Singh A.; Ekavali, A review on Alzheimer\u2019s disease pathophysiology and its management: an update. Pharmacol Rep 2015,67(2),195-203","journal-title":"Pharmacol Rep"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/1567205013666151218150322","volume":"13","author":"Vickers J.C.","year":"2016","unstructured":"Vickers J.C.; Mitew S.; Woodhouse A.; Fernandez-Martos C.M.; Kirkcaldie M.T.; Canty A.J.; McCormack G.H.; King A.E.; Defining the earliest pathological changes of Alzheimer\u2019s disease. Curr Alzheimer Res 2016,13(3),281-287","journal-title":"Curr Alzheimer Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-018-0394-7","volume":"10","author":"Vargas D.M.","year":"2018","unstructured":"Vargas D.M.; De Bastiani M.A.; Zimmer E.R.; Klamt F.; Alzheimer\u2019s disease master regulators analysis: search for potential molecular targets and drug repositioning candidates. Alzheimers Res Ther 2018,10(1),59-70","journal-title":"Alzheimers Res Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/ph11020044","volume":"11","author":"Dur\u00e3es F.","year":"2018","unstructured":"Dur\u00e3es F.; Pinto M.; Sousa E.; Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals (Basel) 2018,11(2),44","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0014-5793(00)02076-7","volume":"483","author":"Nunan J.","year":"2000","unstructured":"Nunan J.; Small D.H.; Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett 2000,483(1),6-10","journal-title":"FEBS Lett"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"Hardy J.","year":"2002","unstructured":"Hardy J.; Selkoe D.J.; The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 2002,297(5580),353-356","journal-title":"Science"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1128\/JVI.03149-13","volume":"88","author":"Chai Q.","year":"2014","unstructured":"Chai Q.; He W.Q.; Zhou M.; Lu H.; Fu Z.F.; Enhancement of blood-brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines\/cytokines induced by rabies virus infection. J Virol 2014,88(9),4698-4710","journal-title":"J Virol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"S411","DOI":"10.3233\/JAD-141467","volume":"42","author":"Wierenga C. E.","year":"2014","unstructured":"Wierenga C. E.; Hays C. C.; Zlatar Z. Z.; Cerebral blood flow\nmeasured by arterial spin labeling MRI as a preclinical marker of\nAlzheimer's disease. J Alzheimer's Dis, 2014,42(Suppl 4)(4),S411-S419","journal-title":"J Alzheimer's Dis,"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10571-015-0261-z","volume":"36","author":"Hays C.C.","year":"2016","unstructured":"Hays C.C.; Zlatar Z.Z.; Wierenga C.E.; The utility of cerebral blood flow as a biomarker of preclinical Alzheimer\u2019s disease. Cell Mol Neurobiol 2016,36(2),167-179","journal-title":"Cell Mol Neurobiol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/jnen\/nlx120","volume":"77","author":"Tiernan C.T.","year":"2018","unstructured":"Tiernan C.T.; Mufson E.J.; Kanaan N.M.; Counts S.E.; Tau Oligomer pathology in nucleus basalis neurons during the progression of Alzheimer Disease. J Neuropathol Exp Neurol 2018,77(3),246-259","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ejphar.2018.10.040","volume":"842","author":"Rahman S.O.","year":"2019","unstructured":"Rahman S.O.; Singh R.K.; Hussain S.; Akhtar M.; Najmi A.K.; A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer\u2019s disease. Eur J Pharmacol 2019,842,208-220","journal-title":"Eur J Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1750-3639.2008.00132.x","volume":"18","author":"Miners J.S.","year":"2008","unstructured":"Miners J.S.; Baig S.; Palmer J.; Palmer L.E.; Kehoe P.G.; Love S.; Abeta-degrading enzymes in Alzheimer\u2019s disease. Brain Pathol 2008,18(2),240-252","journal-title":"Brain Pathol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"15021","DOI":"10.1038\/celldisc.2015.21","volume":"1","author":"Cui J.","year":"2015","unstructured":"Cui J.; Wang X.; Li X.; Wang X.; Zhang C.; Li W.; Zhang Y.; Gu H.; Xie X.; Nan F.; Zhao J.; Pei G.; Targeting the \u03b3-\/\u03b2-secretase interaction reduces \u03b2-amyloid generation and ameliorates Alzheimer\u2019s disease-related pathogenesis. Cell Discov 2015,1(1),15021","journal-title":"Cell Discov"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ejphar.2015.07.043","volume":"764","author":"Kalra J.","year":"2015","unstructured":"Kalra J.; Khan A.; Reducing A\u03b2 load and tau phosphorylation: Emerging perspective for treating Alzheimer\u2019s disease. Eur J Pharmacol 2015,764,571-581","journal-title":"Eur J Pharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.bbi.2016.10.012","volume":"60","author":"Balducci C.","year":"2017","unstructured":"Balducci C.; Frasca A.; Zotti M.; La Vitola P.; Mhillaj E.; Grigoli E.; Iacobellis M.; Grandi F.; Messa M.; Colombo L.; Molteni M.; Trabace L.; Rossetti C.; Salmona M.; Forloni G.; Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by \u03b2-amyloid oligomers in an acute mouse model of Alzheimer\u2019s disease. Brain Behav Immun 2017,60,188-197","journal-title":"Brain Behav Immun"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s00204-019-02538-y","volume":"93","author":"Simunkova M.","year":"2019","unstructured":"Simunkova M.; Alwasel S.H.; Alhazza I.M.; Jomova K.; Kollar V.; Rusko M.; Valko M.; Management of oxidative stress and other pathologies in Alzheimer\u2019s disease. Arch Toxicol 2019,93(9),2491-2513","journal-title":"Arch Toxicol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"10582","DOI":"10.1523\/JNEUROSCI.1736-09.2009","volume":"29","author":"Giuffrida M.L.","year":"2009","unstructured":"Giuffrida M.L.; Caraci F.; Pignataro B.; Cataldo S.; De Bona P.; Bruno V.; Molinaro G.; Pappalardo G.; Messina A.; Palmigiano A.; Garozzo D.; Nicoletti F.; Rizzarelli E.; Copani A.; \u03b2-amyloid monomers are neuroprotective. J Neurosci 2009,29(34),10582-10587","journal-title":"J Neurosci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1515\/REVNEURO.2010.21.2.83","volume":"21","author":"Giuffrida M.L.","year":"2010","unstructured":"Giuffrida M.L.; Caraci F.; De Bona P.; Pappalardo G.; Nicoletti F.; Rizzarelli E.; Copani A.; The monomer state of beta-amyloid: where the Alzheimer\u2019s disease protein meets physiology. Rev Neurosci 2010,21(2),83-93","journal-title":"Rev Neurosci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fncel.2015.00297","volume":"9","author":"Giuffrida M.L.","year":"2015","unstructured":"Giuffrida M.L.; Tomasello M.F.; Pandini G.; Caraci F.; Battaglia G.; Busceti C.; Di Pietro P.; Pappalardo G.; Attanasio F.; Chiechio S.; Bagnoli S.; Nacmias B.; Sorbi S.; Vigneri R.; Rizzarelli E.; Nicoletti F.; Copani A.; Monomeric \u00df-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons. Front Cell Neurosci 2015,9,297","journal-title":"Front Cell Neurosci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.phrs.2010.12.002","volume":"63","author":"Brunden K.R.","year":"2011","unstructured":"Brunden K.R.; Yao Y.; Potuzak J.S.; Ferrer N.I.; Ballatore C.; James M.J.; Hogan A.M.; Trojanowski J.Q.; Smith A.B.; Lee V.M.; The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer\u2019s disease and related tauopathies. Pharmacol Res 2011,63(4),341-351","journal-title":"Pharmacol Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1016\/j.neurobiolaging.2014.05.016","volume":"35","author":"Di Meco A.","year":"2014","unstructured":"Di Meco A.; Lauretti E.; Vagnozzi A.N.; Pratic\u00f2 D.; Zileuton restores memory impairments and reverses amyloid and tau pathology in aged mice. Neurobiol Aging 2014,35,2458-2464","journal-title":"Neurobiol Aging"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40035-018-0139-3","volume":"7","author":"Li H.","year":"2018","unstructured":"Li H.; Liu C-C.; Zheng H.; Huang T.Y.; Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer\u2019s disease -conformist, nonconformist, and realistic prospects for AD pathogenesis. Transl Neurodegener 2018,7(1),34","journal-title":"Transl Neurodegener"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1742-2094-9-145","volume":"9","author":"Huang X.Q.","year":"2012","unstructured":"Huang X.Q.; Zhang X.Y.; Wang X.R.; Yu S.Y.; Fang S.H.; Lu Y.B.; Zhang W.P.; Wei E.Q.; Transforming growth factor \u03b21-induced astrocyte migration is mediated in part by activating 5-lipoxygenase and cysteinyl leukotriene receptor 1. J Neuroinflammation 2012,9,145","journal-title":"J Neuroinflammation"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12974-016-0483-0","volume":"13","author":"Ciaramella A.","year":"2016","unstructured":"Ciaramella A.; Salani F.; Bizzoni F.; Orfei M.D.; Caltagirone C.; Spalletta G.; Boss\u00f9 P.; Myeloid dendritic cells are decreased in peripheral blood of Alzheimer\u2019s disease patients in association with disease progression and severity of depressive symptoms. J Neuroinflammation 2016,13,18","journal-title":"J Neuroinflammation"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2004.06.015","volume":"225","author":"Teaktong T.","year":"2004","unstructured":"Teaktong T.; Graham A.J.; Court J.A.; Perry R.H.; Jaros E.; Johnson M.; Hall R.; Perry E.K.; Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer\u2019s disease and dementia with Lewy bodies: differential neuronal and astroglial pathology. J Neurol Sci 2004,225(1-2),39-49","journal-title":"J Neurol Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2174\/1567202612666151026105610","volume":"13","author":"Singh P.","year":"2016","unstructured":"Singh P.; Sharma B.; Reversal in cognition impairments, cholinergic dysfunction, and cerebral oxidative stress through the modulation of ryanodine receptors (RyRs) and Cysteinyl leukotriene-1 (CysLT1) receptors. Curr Neurovasc Res 2016,13(1),10-21","journal-title":"Curr Neurovasc Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1756-6606-6-6","volume":"6","author":"Tanaka M.","year":"2013","unstructured":"Tanaka M.; Shih P.Y.; Gomi H.; Yoshida T.; Nakai J.; Ando R.; Furuichi T.; Mikoshiba K.; Semyanov A.; Itohara S.; Astrocytic Ca2+ signals are required for the functional integrity of tripartite synapses. Mol Brain 2013,6,6","journal-title":"Mol Brain"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/00207454.2013.833510","volume":"124","author":"Cai Z.","year":"2014","unstructured":"Cai Z.; Hussain M.D.; Yan L.J.; Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer\u2019s disease. Int J Neurosci 2014,124(5),307-321","journal-title":"Int J Neurosci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"Liddelow S.A.","year":"2017","unstructured":"Liddelow S.A.; Guttenplan K.A.; Clarke L.E.; Bennett F.C.; Bohlen C.J.; Schirmer L.; Bennett M.L.; M\u00fcnch A.E.; Chung W.S.; Peterson T.C.; Wilton D.K.; Frouin A.; Napier B.A.; Panicker N.; Kumar M.; Buckwalter M.S.; Rowitch D.H.; Dawson V.L.; Dawson T.M.; Stevens B.; Barres B.A.; Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017,541(7638),481-487","journal-title":"Nature"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3389\/fphar.2019.00840","volume":"10","author":"Biber K.","year":"2019","unstructured":"Biber K.; Bhattacharya A.; Campbell B.M.; Piro J.R.; Rohe M.; Staal R.G.W.; Talanian R.V.; M\u00f6ller T.; Microglial drug targets in ad: opportunities and challenges in drug discovery and development. Front Pharmacol 2019,10,840","journal-title":"Front Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40263-017-0483-3","volume":"31","author":"Ardura-Fabregat A.","year":"2017","unstructured":"Ardura-Fabregat A.; Boddeke E.W.G.M.; Boza-Serrano A.; Brioschi S.; Castro-Gomez S.; Ceyz\u00e9riat K.; Dansokho C.; Dierkes T.; Gelders G.; Heneka M.T.; Hoeijmakers L.; Hoffmann A.; Iaccarino L.; Jahnert S.; Kuhbandner K.; Landreth G.; Lonnemann N.; L\u00f6schmann P.A.; McManus R.M.; Paulus A.; Reemst K.; Sanchez-Caro J.M.; Tiberi A.; Van der Perren A.; Vautheny A.; Venegas C.; Webers A.; Weydt P.; Wijasa T.S.; Xiang X.; Yang Y.; Targeting neuroinflammation to treat Alzheimer\u2019s Disease. CNS Drugs 2017,31(12),1057-1082","journal-title":"CNS Drugs"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/glia.22988","volume":"64","author":"Wes P.D.","year":"2016","unstructured":"Wes P.D.; Sayed F.A.; Bard F.; Gan L.; Targeting microglia for the treatment of Alzheimer\u2019s Disease. Glia 2016,64(10),1710-1732","journal-title":"Glia"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1517\/14728222.2014.988707","volume":"19","author":"McGeer P.L.","year":"2015","unstructured":"McGeer P.L.; McGeer E.G.; Targeting microglia for the treatment of Alzheimer\u2019s disease. Expert Opin Ther Targets 2015,19(4),497-506","journal-title":"Expert Opin Ther Targets"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/brain\/aww017","volume":"139","author":"Hamelin L.","year":"2016","unstructured":"Hamelin L.; Lagarde J.; Doroth\u00e9e G.; Leroy C.; Labit M.; Comley R.A.; de Souza L.C.; Corne H.; Dauphinot L.; Bertoux M.; Dubois B.; Gervais P.; Colliot O.; Potier M.C.; Bottlaender M.; Sarazin M.; Clinical IMABio3 team. Early and protective microglial activation in Alzheimer\u2019s disease: a prospective study using 18F-DPA-714 PET imaging. Brain 2016,139(Pt 4),1252-1264","journal-title":"Brain"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3233\/JAD-143156","volume":"45","author":"Bouvier D.S.","year":"2015","unstructured":"Bouvier D.S.; Murai K.K.; Synergistic actions of microglia and astrocytes in the progression of Alzheimer\u2019s disease. J Alzheimers Dis 2015,45(4),1001-1014","journal-title":"J Alzheimers Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3892\/mmr.2016.4948","volume":"13","author":"Chen W.W.","year":"2016","unstructured":"Chen W.W.; Zhang X.; Huang W.J.; Role of neuroinflammation in neurodegenerative diseases. (Review).  Mol Med Rep 2016,13(4),3391-3396","journal-title":"Mol Med Rep"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/NDT.S75546","volume":"11","author":"Zhang F.","year":"2015","unstructured":"Zhang F.; Jiang L.; Neuroinflammation in Alzheimer\u2019s disease. Neuropsychiatr Dis Treat 2015,11,243-256","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jneuroim.2018.11.010","volume":"326","author":"Thawkar B.S.","year":"2019","unstructured":"Thawkar B.S.; Kaur G.; Inhibitors of NF-\u03baB and P2X7\/NLRP3\/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer\u2019s disease. J Neuroimmunol 2019,326,62-74","journal-title":"J Neuroimmunol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.psyneuen.2018.08.015","volume":"98","author":"Bhattacharya A.","year":"2018","unstructured":"Bhattacharya A.; Jones D.N.C.; Emerging role of the P2X7-NLRP3-IL1\u03b2 pathway in mood disorders. Psychoneuroendocrinology 2018,98,95-100","journal-title":"Psychoneuroendocrinology"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3233\/JAD-170706","volume":"62","author":"McGeer P.L.","year":"2018","unstructured":"McGeer P.L.; Guo J.P.; Lee M.; Kennedy K.; McGeer E.G.; Alzheimer\u2019s Disease Can Be Spared by nonsteroidal anti-inflammatory drugs. J Alzheimers Dis 2018,62(3),1219-1222","journal-title":"J Alzheimers Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1172\/JCI96209","volume":"128","author":"Rangasamy S.B.","year":"2018","unstructured":"Rangasamy S.B.; Jana M.; Roy A.; Corbett G.T.; Kundu M.; Chandra S.; Mondal S.; Dasarathi S.; Mufson E.J.; Mishra R.K.; Luan C.H.; Bennett D.A.; Pahan K.; Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer\u2019s pathology. J Clin Invest 2018,128(10),4297-4312","journal-title":"J Clin Invest"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.neurobiolaging.2018.06.020","volume":"70","author":"Pourbadie H.G.","year":"2018","unstructured":"Pourbadie H.G.; Sayyah M.; Khoshkholgh-Sima B.; Choopani S.; Nategh M.; Motamedi F.; Shokrgozar M.A.; Early minor stimulation of microglial TLR2 and TLR4 receptors attenuates Alzheimer\u2019s disease-related cognitive deficit in rats: behavioral, molecular, and electrophysiological evidence. Neurobiol Aging 2018,70,203-216","journal-title":"Neurobiol Aging"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/14728222.2019.1575811","volume":"23","author":"Illes P.","year":"2019","unstructured":"Illes P.; Rubini P.; Huang L.; Tang Y.; The P2X7 receptor: a new therapeutic target in Alzheimer\u2019s disease. Expert Opin Ther Targets 2019,23(3),165-176","journal-title":"Expert Opin Ther Targets"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/glia.23001","volume":"64","author":"Bhattacharya A.","year":"2016","unstructured":"Bhattacharya A.; Biber K.; The microglial ATP-gated ion channel P2X7 as a CNS drug target. Glia 2016,64(10),1772-1787","journal-title":"Glia"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41583-018-0055-7","volume":"19","author":"Heneka M.T.","year":"2018","unstructured":"Heneka M.T.; McManus R.M.; Latz E.; Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci 2018,19(10),610-621","journal-title":"Nat Rev Neurosci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.expneurol.2012.04.021","volume":"236","author":"Thal D.R.","year":"2012","unstructured":"Thal D.R.; The role of astrocytes in amyloid \u03b2-protein toxicity and clearance. Exp Neurol 2012,236(1),1-5","journal-title":"Exp Neurol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1152\/physrev.00041.2013","volume":"94","author":"Pekny M.","year":"2014","unstructured":"Pekny M.; Pekna M.; Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol Rev 2014,94(4),1077-1098","journal-title":"Physiol Rev"},{"key":"ref=60","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6435861","volume":"2018","author":"Wojsiat J.","year":"2018","unstructured":"Wojsiat J.; Zoltowska K.M.; Laskowska-Kaszub K.; Wojda U.; Oxidant\/antioxidant imbalance in Alzheimer\u2019s Disease: therapeutic and diagnostic prospects. Oxid Med Cell Longev 2018,2018","journal-title":"Oxid Med Cell Longev"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12264-013-1423-y","volume":"30","author":"Chen Z.","year":"2014","unstructured":"Chen Z.; Zhong C.; Oxidative stress in Alzheimer\u2019s disease. Neurosci Bull 2014,30(2),271-281","journal-title":"Neurosci Bull"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1039\/c0mt00074d","volume":"3","author":"Bonda D.J.","year":"2011","unstructured":"Bonda D.J.; Lee H.G.; Blair J.A.; Zhu X.; Perry G.; Smith M.A.; Role of metal dyshomeostasis in Alzheimer\u2019s disease. Metallomics 2011,3(3),267-270","journal-title":"Metallomics"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1039\/c1mt90005f","volume":"3","author":"Brown D.R.","year":"2011","unstructured":"Brown D.R.; Metals in neurodegenerative disease. Metallomics 2011,3(3),226-228","journal-title":"Metallomics"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2174\/0929867324666170518094404","volume":"25","author":"Lanza V.","year":"2018","unstructured":"Lanza V.; Milardi D.; Di Natale G.; Pappalardo G.; Repurposing of Copper(II)-chelating drugs for the treatment of neurodegenerative diseases. Curr Med Chem 2018,25(4),525-539","journal-title":"Curr Med Chem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fnmol.2017.00339","volume":"10","author":"Li Y.","year":"2017","unstructured":"Li Y.; Jiao Q.; Xu H.; Du X.; Shi L.; Jia F.; Jiang H.; Biometal dyshomeostasis and toxic metal accumulations in the development of Alzheimer\u2019s Disease. Front Mol Neurosci 2017,10,339","journal-title":"Front Mol Neurosci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1089\/ars.2017.7272","volume":"28","author":"Garza-Lomb\u00f3 C.","year":"2018","unstructured":"Garza-Lomb\u00f3 C.; Posadas Y.; Quintanar L.; Gonsebatt M.E.; Franco R.; Neurotoxicity linked to dysfunctional metal ion homeostasis and xenobiotic metal exposure: redox signaling and oxidative stress. Antioxid Redox Signal 2018,28(18),1669-1703","journal-title":"Antioxid Redox Signal"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1021\/acschemneuro.5b00073","volume":"6","author":"Ong W-Y.","year":"2015","unstructured":"Ong W-Y.; Farooqui T.; Kokotos G.; Farooqui A.A.; Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders. ACS Chem Neurosci 2015,6(6),814-831","journal-title":"ACS Chem Neurosci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.brainres.2014.10.015","volume":"1590","author":"Ha J.S.","year":"2014","unstructured":"Ha J.S.; Dho S.H.; Youm T.H.; Kwon K.S.; Park S.S.; Astrocytic phospholipase A2 contributes to neuronal glutamate toxicity. Brain Res 2014,1590,97-106","journal-title":"Brain Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"Sweeney M.D.","year":"2018","unstructured":"Sweeney M.D.; Sagare A.P.; Zlokovic B.V.; Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 2018,14(3),133-150","journal-title":"Nat Rev Neurol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00401-016-1606-5","volume":"132","author":"Engelhardt B.","year":"2016","unstructured":"Engelhardt B.; Carare R.O.; Bechmann I.; Fl\u00fcgel A.; Laman J.D.; Weller R.O.; Vascular, glial, and lymphatic immune gateways of the central nervous system. Acta Neuropathol 2016,132(3),317-338","journal-title":"Acta Neuropathol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/ijms20020381","volume":"20","author":"Wong K.H.","year":"2019","unstructured":"Wong K.H.; Riaz M.K.; Xie Y.; Zhang X.; Liu Q.; Chen H.; Bian Z.; Chen X.; Lu A.; Yang Z.; Review of current strategies for delivering alzheimer\u2019s disease drugs across the blood-brain barrier. Int J Mol Sci 2019,20(2),381-406","journal-title":"Int J Mol Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3233\/JAD-2011-102034","volume":"27","author":"Fisher Y.","year":"2011","unstructured":"Fisher Y.; Nemirovsky A.; Baron R.; Monsonego A.; Dendritic cells regulate amyloid-\u03b2-specific T-cell entry into the brain: the role of perivascular amyloid-\u03b2. J Alzheimers Dis 2011,27(1),99-111","journal-title":"J Alzheimers Dis"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jnc.13932","volume":"140","author":"Salminen A.","year":"2017","unstructured":"Salminen A.; Kauppinen A.; Kaarniranta K.; Hypoxia\/ischemia activate processing of Amyloid Precursor Protein: impact of vascular dysfunction in the pathogenesis of Alzheimer\u2019s disease. J Neurochem 2017,140(4),536-549","journal-title":"J Neurochem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1017\/S1461145711000149","volume":"15","author":"Chen C.H.","year":"2012","unstructured":"Chen C.H.; Zhou W.; Liu S.; Deng Y.; Cai F.; Tone M.; Tone Y.; Tong Y.; Song W.; Increased NF-\u03baB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer\u2019s disease. Int J Neuropsychopharmacol 2012,15(1),77-90","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00401-016-1570-0","volume":"131","author":"Montagne A.","year":"2016","unstructured":"Montagne A.; Nation D.A.; Pa J.; Sweeney M.D.; Toga A.W.; Zlokovic B.V.; Brain imaging of neurovascular dysfunction in Alzheimer\u2019s disease. Acta Neuropathol 2016,131(5),687-707","journal-title":"Acta Neuropathol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1185\/03007995.2014.939167","volume":"30","author":"Henley D.B.","year":"2014","unstructured":"Henley D.B.; Sundell K.L.; Sethuraman G.; Dowsett S.A.; May P.C.; Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings. Curr Med Res Opin 2014,30(10),2021-2032","journal-title":"Curr Med Res Opin"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.brainresbull.2016.03.010","volume":"126","author":"Chu J.","year":"2016","unstructured":"Chu J.; Pratic\u00f2 D.; The 5-Lipoxygenase as modulator of Alzheimer\u2019s \u03b3-secretase and therapeutic target. Brain Res Bull 2016,126(Pt 2),207-212","journal-title":"Brain Res Bull"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1471-4159.2011.07476.x","volume":"120","author":"Ghosh A.K.","year":"2012","unstructured":"Ghosh A.K.; Brindisi M.; Tang J.; Developing \u03b2-secretase inhibitors for treatment of Alzheimer\u2019s disease. J Neurochem 2012,120(1)(Suppl. 1),71-83","journal-title":"J Neurochem"},{"key":"ref=79","first-page":"189","volume":"14","author":"Zhang C.","year":"2012","unstructured":"Zhang C.; Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer\u2019s disease. Discov Med 2012,14(76),189-197","journal-title":"Discov Med"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/WAD.0b013e31823b2728","volume":"26","author":"Llano D.A.","year":"2012","unstructured":"Llano D.A.; Li J.; Waring J.F.; Ellis T.; Devanarayan V.; Witte D.G.; Lenz R.A.; Cerebrospinal fluid cytokine dynamics differ between Alzheimer disease patients and elderly controls. Alzheimer Dis Assoc Disord 2012,26(4),322-328","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/JAD-130497","volume":"37","author":"Gezen-Ak D.","year":"2013","unstructured":"Gezen-Ak D.; Dursun E.; Hana\u011fas\u0131 H.; Bilgi\u00e7 B.; Lohman E.; Araz \u00d6.S.; Atasoy \u0130.L.; Alayl\u0131o\u011flu M.; \u00d6nal B.; G\u00fcrvit H.; Y\u0131lmazer S.; BDNF, TNF\u03b1, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer\u2019s disease or mild cognitive impairment. J Alzheimers Dis 2013,37(1),185-195","journal-title":"J Alzheimers Dis"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/gps.3816","volume":"28","author":"Honma T.","year":"2013","unstructured":"Honma T.; Hatta K.; Hitomi Y.; Kambayashi Y.; Hibino Y.; Konoshita T.; Nakamura H.; Increased systemic inflammatory interleukin-1\u00df and interleukin-6 during agitation as predictors of Alzheimer\u2019s disease. Int J Geriatr Psychiatry 2013,28(3),233-241","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=83","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/484613","volume":"2013","author":"Hsieh H.L.","year":"2013","unstructured":"Hsieh H.L.; Yang C.M.; Role of redox signaling in neuroinflammation and neurodegenerative diseases. BioMed Res Int 2013,2013","journal-title":"BioMed Res Int"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"25959","DOI":"10.3390\/ijms161125939","volume":"16","author":"Falkowska A.","year":"2015","unstructured":"Falkowska A.; Gutowska I.; Goschorska M.; Nowacki P.; Chlubek D.; Baranowska-Bosiacka I.; Energy metabolism of the brain, including the cooperation between astrocytes and neurons, especially in the context of glycogen metabolism. Int J Mol Sci 2015,16(11),25959-25981","journal-title":"Int J Mol Sci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neulet.2013.12.071","volume":"565","author":"Pekny M.","year":"2014","unstructured":"Pekny M.; Wilhelmsson U.; Pekna M.; The dual role of astrocyte activation and reactive gliosis. Neurosci Lett 2014,565,30-38","journal-title":"Neurosci Lett"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/bib\/bbv048","volume":"17","author":"Siavelis J.C.","year":"2016","unstructured":"Siavelis J.C.; Bourdakou M.M.; Athanasiadis E.I.; Spyrou G.M.; Nikita K.S.; Bioinformatics methods in drug repurposing for Alzheimer\u2019s disease. Brief Bioinform 2016,17(2),322-335","journal-title":"Brief Bioinform"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41398-019-0555-x","volume":"9","author":"Williams G.","year":"2019","unstructured":"Williams G.; Gatt A.; Clarke E.; Corcoran J.; Doherty P.; Chambers D.; Ballard C.; Drug repurposing for Alzheimer\u2019s disease based on transcriptional profiling of human iPSC-derived cortical neurons. Transl Psychiatry 2019,9(1),220","journal-title":"Transl Psychiatry"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s13311-014-0325-7","volume":"12","author":"Kim T-W.","year":"2015","unstructured":"Kim T-W.; Drug repositioning approaches for the discovery of new therapeutics for Alzheimer\u2019s disease. Neurotherapeutics 2015,12(1),132-142","journal-title":"Neurotherapeutics"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuint.2014.05.006","volume":"75","author":"Lai J.","year":"2014","unstructured":"Lai J.; Mei Z.L.; Wang H.; Hu M.; Long Y.; Miao M.X.; Li N.; Hong H.; Montelukast rescues primary neurons against A\u03b21-42-induced toxicity through inhibiting CysLT1R-mediated NF-\u03baB signaling. Neurochem Int 2014,75,26-31","journal-title":"Neurochem Int"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/1874205X01711010007","volume":"11","author":"Rozin S.I.","year":"2017","unstructured":"Rozin S.I.; Case series using montelukast in patients with memory loss and dementia. Open Neurol J 2017,11,7-10","journal-title":"Open Neurol J"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1159\/000338818","volume":"159","author":"Ilarraza R.","year":"2012","unstructured":"Ilarraza R.; Wu Y.; Adamko D.J.; Montelukast inhibits leukotriene stimulation of human dendritic cells in vitro. Int Arch Allergy Immunol 2012,159(4),422-427","journal-title":"Int Arch Allergy Immunol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pbb.2012.07.015","volume":"103","author":"Kumar A.","year":"2012","unstructured":"Kumar A.; Prakash A.; Pahwa D.; Mishra J.; Montelukast potentiates the protective effect of rofecoxib against kainic acid-induced cognitive dysfunction in rats. Pharmacol Biochem Behav 2012,103(1),43-52","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/ejcts\/ezs312","volume":"43","author":"Al-Amran F.G.","year":"2013","unstructured":"Al-Amran F.G.; Hadi N.R.; Hashim A.M.; Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats. Eur J Cardiothorac Surg 2013,43(2),421-427","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.neuropharm.2014.01.011","volume":"79","author":"Lai J.","year":"2014","unstructured":"Lai J.; Hu M.; Wang H.; Hu M.; Long Y.; Miao M.X.; Li J.C.; Wang X.B.; Kong L.Y.; Hong H.; Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates A\u03b21-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice. Neuropharmacology 2014,79,707-714","journal-title":"Neuropharmacology"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s10753-013-9657-4","volume":"36","author":"Shi S.S.","year":"2013","unstructured":"Shi S.S.; Yang W.Z.; Tu X.K.; Wang C.H.; Chen C.M.; Chen Y.; 5-Lipoxygenase inhibitor zileuton inhibits neuronal apoptosis following focal cerebral ischemia. Inflammation 2013,36(6),1209-1217","journal-title":"Inflammation"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3389\/fncel.2014.00436","volume":"8","author":"Joshi Y.B.","year":"2015","unstructured":"Joshi Y.B.; Pratic\u00f2 D.; The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer\u2019s disease phenotype. Front Cell Neurosci 2015,8(436),436","journal-title":"Front Cell Neurosci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.biopsych.2015.01.015","volume":"78","author":"Giannopoulos P.F.","year":"2015","unstructured":"Giannopoulos P.F.; Chu J.; Sperow M.; Li J.G.; Yu W.H.; Kirby L.G.; Abood M.; Pratic\u00f2 D.; Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy. Biol Psychiatry 2015,78(10),693-701","journal-title":"Biol Psychiatry"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ana.23642","volume":"72","author":"Chu J.","year":"2012","unstructured":"Chu J.; Giannopoulos P.F.; Ceballos-Diaz C.; Golde T.E.; Pratic\u00f2 D.; 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol 2012,72(3),442-454","journal-title":"Ann Neurol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.pnpbp.2010.07.032","volume":"35","author":"Manev H.","year":"2011","unstructured":"Manev H.; Chen H.; Dzitoyeva S.; Manev R.; Cyclooxygenases and 5-lipoxygenase in Alzheimer\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 2011,35(2),315-319","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1369\/jhc.2008.951855","volume":"56","author":"Ikonomovic M.D.","year":"2008","unstructured":"Ikonomovic M.D.; Abrahamson E.E.; Uz T.; Manev H.; Dekosky S.T.; Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer\u2019s disease. J Histochem Cytochem 2008,56(12),1065-1073","journal-title":"J Histochem Cytochem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1096\/fj.07-9131.com","volume":"22","author":"Firuzi O.","year":"2008","unstructured":"Firuzi O.; Zhuo J.; Chinnici C.M.; Wisniewski T.; Pratic\u00f2 D.; 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer\u2019s disease. FASEB J 2008,22(4),1169-1178","journal-title":"FASEB J"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3233\/JAD-161006","volume":"60","author":"Sheng M.","year":"2017","unstructured":"Sheng M.; Lu H.; Liu P.; Li Y.; Ravi H.; Peng S-L.; Diaz-Arrastia R.; Devous M.D.; Womack K.B.; Sildenafil improves vascular and metabolic function in patients with Alzheimer\u2019s Disease. J Alzheimers Dis 2017,60(4),1351-1364","journal-title":"J Alzheimers Dis"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2147\/NDT.S61309","volume":"11","author":"Tousi B.","year":"2015","unstructured":"Tousi B.; The emerging role of bexarotene in the treatment of Alzheimer\u2019s disease: current evidence. Neuropsychiatr Dis Treat 2015,11,311-315","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=104","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6167","volume":"2","author":"Okereke O.I.","year":"2019","unstructured":"Okereke O.I.; Meadows M-E.; More evidence of an inverse association between cancer and Alzheimer Disease. JAMA Netw Open 2019,2(6)","journal-title":"JAMA Netw Open"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2174\/1389200218666170607101622","volume":"18","author":"Shoaib M.","year":"2017","unstructured":"Shoaib M.; Kamal M.A.; Rizvi S.M.D.; Repurposed drugs as potential therapeutic candidates for the management of Alzheimer\u2019s Disease. Curr Drug Metab 2017,18(9),842-852","journal-title":"Curr Drug Metab"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.jalz.2018.06.3040","volume":"14","author":"Moir R.D.","year":"2018","unstructured":"Moir R.D.; Lathe R.; Tanzi R.E.; The antimicrobial protection hypothesis of Alzheimer\u2019s disease. Alzheimers Dement 2018,14(12),1602-1614","journal-title":"Alzheimers Dement"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","volume":"5","author":"Cummings J.","year":"2019","unstructured":"Cummings J.; Lee G.; Ritter A.; Sabbagh M.; Zhong K.; Alzheimer\u2019s disease drug development pipeline: 2019. Alzheimers Dement (N Y) 2019,5,272-293","journal-title":"Alzheimers Dement (N Y)"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X18666200128121920","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/178733\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X18666200128121920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T14:22:04Z","timestamp":1655389324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178733\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x18666200128121920","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}